Stratton Matthew S, McKinsey Timothy A
Department of Medicine, Division of Cardiology and Center for Fibrosis Research and Translation, University of Colorado Denver, 12700 E. 19th Ave, Aurora, CO 80045-0508, United States.
Department of Medicine, Division of Cardiology and Center for Fibrosis Research and Translation, University of Colorado Denver, 12700 E. 19th Ave, Aurora, CO 80045-0508, United States.
J Mol Cell Cardiol. 2016 Mar;92:206-13. doi: 10.1016/j.yjmcc.2016.02.011. Epub 2016 Feb 12.
Fibrosis is defined as excess deposition of extracellular matrix (ECM), resulting in tissue scarring and organ dysfunction. In the heart, fibrosis may be reparative, replacing areas of myocyte loss with a structural scar following infarction, or reactive, which is triggered in the absence of cell death and involves interstitial ECM deposition in response to long-lasting stress. Interstitial fibrosis can increase the passive stiffness of the myocardium, resulting in impaired relaxation and diastolic dysfunction. Additionally, fibrosis can lead to disruption of electrical conduction in the heart, causing arrhythmias, and can limit myocyte oxygen availability and thus exacerbate myocardial ischemia. Here, we review recent studies that have illustrated key roles for epigenetic events in the control of pro-fibrotic gene expression, and highlight the potential of small molecules that target epigenetic regulators as a means of treating fibrotic cardiac diseases.
纤维化被定义为细胞外基质(ECM)过度沉积,导致组织瘢痕形成和器官功能障碍。在心脏中,纤维化可能是修复性的,在梗死之后用结构性瘢痕替代心肌细胞丢失的区域,或者是反应性的,在没有细胞死亡的情况下触发,并且涉及间质ECM沉积以响应长期应激。间质纤维化可增加心肌的被动僵硬度,导致舒张功能受损和舒张功能障碍。此外,纤维化可导致心脏电传导中断,引起心律失常,并可限制心肌细胞的氧供应,从而加重心肌缺血。在此,我们综述了最近的研究,这些研究阐明了表观遗传事件在控制促纤维化基因表达中的关键作用,并强调了靶向表观遗传调节因子的小分子作为治疗纤维化心脏病手段的潜力。